In Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer ’s Drug

The agency faced criticism for approving Aduhelm for all Alzheimer ’s patients. Now it recommends that the drug be given only to those with mild symptoms.

https://www.nytimes.com/2021/07/08/health/aduhelm-alzheimers-fda.html

Source: NYT Health - July 8, 2021 Category: Consumer Health News Authors: Rebecca Robbins and Pam Belluck Tags: Alzheimer ' s Disease Labeling and Labels (Product) Aduhelm (Drug) Drugs (Pharmaceuticals) Clinical Trials Food and Drug Administration Biogen Inc Source Type: news

More News: Alzheimer's | Clinical Trials | Food and Drug Administration (FDA) | Health